Clinical Trials
45 trialsTTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
ImPRESS
Oslo University Hospital
TaRRGET
Prof. Franciszek Lukaszczyk Memorial Oncology Center
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
OptimalTTF-2
University of Aarhus
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Emory University
Phase 2 Study of CAN008 in Subjects With GBM
CANbridge Life Sciences Ltd.
SonoFIRST
Assistance Publique - Hôpitaux de Paris
Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma
Huashan Hospital
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)
Matrix Biomed, Inc.
Niraparib Combined With Radiotherapy in rGBM
Tianjin Huanhu Hospital
Pilot Study of Elemene in Treating Patients With Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
Peking Union Medical College Hospital
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
Shandong Cancer Hospital and Institute
Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen
Sun Yat-sen University
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
AEO
MetVital, Inc.
GlioCave/NOA17
Technical University of Munich
Pemetrexed Disodium in Treating Patients With Recurrent Malignant Gliomas, Primary CNS Lymphoma, or Brain Metastases
Northwestern University
RACTAC
Regina Elena Cancer Institute
Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma
People's Hospital of Guangxi Zhuang Autonomous Region
GBM
Immunitor LLC
uPAR-PET/MRI in Glioblastoma Multiforme
Rigshospitalet, Denmark
Hypofractionated Radiation Therapy for Glioblastoma
Instituto do Cancer do Estado de São Paulo
Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma
McGill University Health Centre/Research Institute of the McGill University Health Centre
Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients
Seoul National University Hospital
Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)
China Medical University Hospital
Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
Zhejiang Cancer Hospital
Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Arno Therapeutics
ALA
Legacy Health System
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Procarbazine and Lomustine in Recurrent Glioblastoma
Incheon St.Mary's Hospital
ExCentric
Northern Sydney and Central Coast Area Health Service
GLIAA
University Hospital Freiburg
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Adnexus, A Bristol-Myers Squibb R&D Company
SURGE01-07
Medical University Innsbruck
PATSGO
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
HBO
Neurological Surgery, P.C.
A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes.
Medanta Institute of Clinical Research
Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Bradmer Pharmaceuticals Inc.
131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma
TransMolecular
Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma
University of Zurich